Phosphatidylinositol 3-kinase-C2β inhibits cisplatin-mediated apoptosis via the Akt pathway in oesophageal squamous cell carcinoma

Journal of International Medical Research

Volumn 39, Issue 4, 2011, Pages 1319-1332

  Liu, Z ^a   Sun, C ^b   Zhang, Y ^a   Ji, Z ^a   Yang, G ^a  

^a ZHENGZHOU UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Anticancer agents; Apoptosis; Cisplatin; Drug resistance; Metastasis; Oesophageal squamous cell carcinoma; Phosphatidylinositol 3 kinase

Indexed keywords

CASPASE 3; CISPLATIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE C2BETA; PROTEIN KINASE B; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SENSITIVITY; ENZYME PHOSPHORYLATION; ESOPHAGUS CARCINOMA; FEMALE; GENE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PIK3C2B GENE; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

EID: 80052230677     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001103900419     Document Type: Article

References (37)

1. Parkin DM, Bray F, Ferlay J, et al: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Polee MB, Kok TC, Siersema PD, et al: Phase II study of the combination cisplatin, etoposide, 5-fluorouracil and folinic acid in patients with advanced squamous cell carcinoma of the esophagus. Anticancer Drugs 2001; 12: 513-517.
3. Ilson DH, Kelsen DP: Management of esophageal cancer. Oncology (Williston Park) 1996; 10: 1385-1402.
4. Ohmichi M, Hayakawa J, Tasaka K, et al: Mechanisms of platinum drug resistance. Trends Pharmacol Sci 2005; 26: 113-116.
5. Chu G: Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem 1994; 269: 787-790.
6. Kelland LR: A new resistance mechanism to cisplatin? Drug Resist Updat 2000; 3: 139-141.
7. Kelland LR: Preclinical perspectives on platinum resistance. Drugs 2000; 59(suppl 4): 1-8; discussion 37-38.
8. Barry MA, Behnke CA, Eastman A: Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 1990; 40: 2353-2362.
9. Franke TF, Hornik CP, Segev L, et al: PI3K/Akt and apoptosis: size matters. Oncogene 2003; 22: 8983-8998.
10. Yang X, Fraser M, Abedini MR, et al: Regulation of apoptosis-inducing factor-mediated, cisplatin-induced apoptosis by Akt. Br J Cancer 2008; 98: 803-808.
11. Engelman JA: Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009; 9: 550-562.
12. Hayakawa J, Ohmichi M, Kurachi H, et al: Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. Cancer Res 2000; 60: 5988-5994.
13. Tran H, Brunet A, Grenier JM, et al: DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein. Science 2002; 296: 530-534.
14. Kimura A, Ohmichi M, Kawagoe J, et al: Induction of hTERT expression and phosphorylation by estrogen via Akt cascade in human ovarian cancer cell lines. Oncogene 2004; 23: 4505-4515.
15. Mabuchi S, Ohmichi M, Nishio Y, et al: Inhibition of NFκB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J Biol Chem 2004; 279: 23477-23485.
16. Wheeler M, Domin J: The N-terminus of phosphoinositide 3-kinase-C2β regulates lipid kinase activity and binding to clathrin. J Cell Physiol 2006; 206: 586-593.
17. Maffucci T, Cooke F, Foster FM, et al: Class II phosphoinositide 3-kinase defines a novel signaling pathway in cell migration. J Cell Biol 2005; 169: 789-799.
18. Domin J, Harper L, Aubyn D, et al: The class II phosphoinositide 3-kinase PI3K-C2β regulates cell migration by a PtdIns3P dependent mechanism. J Cell Physiol 2005; 205: 452-462.
19. Das M, Scappini E, Martin NP, et al: Regulation of neuron survival through an intersectinphosphoinositide 3'-kinase C2β-AKT pathway. Mol Cell Biol 2007; 27: 7906-7917.
20. Elis W, Triantafellow E, Wolters NM, et al: Down-regulation of class II phosphoinositide 3-kinase α expression below a critical threshold induces apoptotic cell death. Mol Cancer Res 2008; 6: 614-623.
21. Brunet A, Datta SR, Greenberg ME: Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr Opin Neurobiol 2001; 11: 297-305.
22. Domin J, Pages F, Volinia S, et al: Cloning of a human phosphoinositide 3-kinase with a C2 domain that displays reduced sensitivity to the inhibitor wortmannin. Biochem J 1997; 326: 139-147.
23. Višnjić D, Crljen V, Curić J, et al: The activation of nuclear phosphoinositide 3-kinase C2β in all-trans-retinoic acid-differentiated HL-60 cells. FEBS Lett 2002; 529: 268-274.
24. El Sheikh SS, Domin J, Tomtitchong P, et al: Topographical expression of class IA and class II phosphoinositide 3-kinase enzymes in normal human tissues is consistent with a role in differentiation. BMC Clin Pathol 2003; 3: 4.
25. Marras E, Concari P, Cortellezzi L, et al: Involvement of PI3K in PKCε-mediated oncogenic signal in rat colonic epithelial cells. Int J Oncol 2001; 19: 395-399.
26. Traer CJ, Foster FM, Abraham SM, et al: Are class II phosphoinositide 3-kinases potential targets for anticancer therapies? Bull Cancer 2006; 93: E53-E58.
27. Kang S, Song J, Kang J, et al: Suppression of the α-isoform of class II phosphoinositide 3-kinase gene expression leads to apoptotic cell death. Biochem Biophys Res Commun 2005; 329: 6-10.
28. Sato N, Fukushima N, Maitra A, et al: Gene expression profiling identifies genes associated with invasive intraductal papillary mucinous neoplasms of the pancreas. Am J Pathol 2004; 164: 903-914.
29. Armstrong SA, Staunton JE, Silverman LB, et al: MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002; 30: 41-47.
30. Rodriguez-Viciana P, Warne PH, Khwaja A, et al: Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 1997; 89: 457-467.
31. Arcaro A, Volinia S, Zvelebil MJ, et al: Human phosphoinositide 3-kinase C2β, the role of calcium and the C2 domain in enzyme activity. J Biol Chem 1998; 273: 33082-33090.
32. Katso RM, Pardo OE, Palamidessi A, et al: Phosphoinositide 3-kinase C2β regulates cytoskeletal organization and cell migration via Rac-dependent mechanisms. Mol Biol Cell 2006; 17: 3729-3744.
33. Arafa el-SA, Zhu Q, Barakat BM, et al: Tangeretin sensitizes cisplatin-resistant human ovarian cancer cells through down regulation of phosphoinositide 3-kinase/Akt signaling pathway. Cancer Res 2009; 69: 8910-8917.
34. Tsai WS, Yeow WS, Chua A, et al: Enhancement of Apo2L/TRAIL-mediated cytotoxicity in esophageal cancer cells by cisplatin. Mol Cancer Ther 2006; 5: 2977-2990.
35. Cheng JQ, Jiang X, Fraser M, et al: Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway. Drug Resist Updat 2002; 5: 131-146.
36. Wu H, Cao Y, Weng D, et al: Effect of tumor suppressor gene PTEN on the resistance to cisplatin in human ovarian cancer cell lines and related mechanisms. Cancer Lett 2008; 271: 260-271.
37. Gajewski TF, Thompson CB: Apoptosis meets signal transduction: elimination of a BAD influence. Cell 1996; 87: 589-592.